Henogen opens new biopharmaceutical clinical supply plant

21-Oct-2004

The new biopharmaceutical clinical supply plant of Henogen was inaugurated today in a ceremony attended by the Wallonia Minister-President Jean-Claude Van Cauwenberghe. "These new cGMP facilities, dedicated to the mammalian cells culture, represent a total investment of 10 million Euros", said Dr Alex Bollen, CEO ; "they feature a park of 3L & 15L bioreactors used for process development purposes and a cGMP 300L bioreactor train, operated in both fed-batch and perfusion modes, able to deliver clinical-grade biologicals at a scale appropriate to the phase I to III clinical trials", he added.

This investment extends the existing know-how of Henogen 'from gene to clinical product' to the large scale production of clinical grade monoclonal antibodies and recombinant proteins made by mammalian cells, which is a very fast growing market.

These new facilities will generate additional revenues to the existing ones (forecast 2004: 7 MEUR) in order to boost the clinical development of its proprietary products e.g. a recombinant human tissue factor derivative, currently in clinical trials as well as other undisclosed programs.

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous